Journal of Nuclear Medicine Impact Factor Rises Again

June 29, 2022

Reston, VA — The Journal of Nuclear Medicine has again achieved the highest impact factor in its history, ranking fourth among all medical imaging journals worldwide, according to new data just released in Clarivate's 2021 Journal Citation Reports. JNM is the flagship publication of the Society of Nuclear Medicine and Molecular Imaging.

“This continued rise in visibility emphasizes not only the high quality of the journal but also the rise in importance of nuclear medicine as a whole,” said Editor-in-Chief Johannes Czernin, MD, professor of molecular and medical pharmacology and chief of the Ahmanson Translational Theranostics Division at the UCLA David Geffen School of Medicine, Los Angeles, California. “Revolutionary advances in nuclear medicine research are resulting in revolutionary care for patients,” said Czernin.

JNM’s impact factor increased more than 10% over last year, from 10.057 (2020) to 11.082 (2021). With 35,215 total citations, the journal is fourth in impact factor and third in Journal Citation Indicator among 200 journals included in the medical imaging category. Other key statistics: JNM’s total citations increased 7%, and its 5-year impact factor increased almost 15%. Among nuclear medicine journals, JNM continues to have the highest impact factor, total citations, 5-year impact factor, Eigenfactor score and article influence score.

“This is a tribute to the contributions of diverse scientists from all areas of the field,” Czernin said, “from advances in imaging instrumentation to important aspects of theranostics and therapeutic approaches.” JNM has highlighted some of those advances in recent supplements focused on personalized dosimetry for cancer therapy, nuclear endocrinology and molecular imaging of neurodegeneration.

The impact factor—a quantitative measure of the frequency with which an article in a journal is cited—is used to gauge the overall influence of a journal within scientific, professional and academic communities.

“I am grateful for the support of SNMMI and its Publications Committee, the valuable contributions of our staff, the vital input from our Editorial Board and reviewers, and the dedication and expertise of the team of associate editors whose work made this success possible,” Czernin said.

Visit JNM’s website for the latest nuclear medicine research, and follow us on Twitter, Facebook and LinkedIn.

###

About JNM and the Society of Nuclear Medicine and Molecular Imaging

The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed 15 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.

JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.